Medindia

X

Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008

Wednesday, August 6, 2008 General News J E 4
Advertisement
SAN DIEGO, Aug. 5 Orexigen(R) Therapeutics, Inc.(Nasdaq: OREX), a biopharmaceutical company focused on the treatment ofcentral nervous system disorders, including obesity, will announce financialresults for its second quarter ended June 30, 2008, on Thursday, August 7,2008, after the markets close. The announcement will be followed by a livewebcast and conference call at 2:00 p.m. Pacific Time.

Orexigen management will host the call and webcast to discuss results forthe second quarter ended June 30, 2008, and recent business highlights. Thelive call may be accessed by phone by calling (800) 860-2442 (domestic) or(412) 858-4600 (international). The webcast can be accessed live on theinvestor relations section of the Company's Web site athttp://www.orexigen.com and will be archived for 14 days following the call.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on thedevelopment of pharmaceutical product candidates for the treatment of centralnervous system disorders, including obesity. The Company's lead combinationproduct candidates targeted for obesity are Contrave(R), which is in Phase IIIclinical trials, and Empatic(TM), which is in the later stages of Phase IIclinical development. Both product candidates take advantage of the Company'sunderstanding of how the brain appears to regulate appetite and energyexpenditure, as well as the mechanisms that come into play to limit weightloss over time. Each product candidate is designed to act on a specific groupof neurons in the central nervous system with the goal of achieving appetitesuppression and sustained weight loss. Further information about the Companycan be found at http://www.orexigen.com.

SOURCE Orexigen Therapeutics, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Genomic Health Announces Second Quarter 2008 Finan...
S
HLTH Corporation Announces Second Quarter Financia...